...
search icon
vrna-img

Verona Pharma PLC ADR, Common Stock

VRNA

NMQ

$53.22

-$0.47

(-0.88%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.49B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
988.14K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.42
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$11.39 L
$55.91 H
$53.22

About Verona Pharma PLC ADR, Common Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameVRNASectorS&P500
1-Week Return-0.52%3.54%-0.58%
1-Month Return13.19%7.51%1.89%
3-Month Return60.74%-0.85%3.24%
6-Month Return135.38%-1.67%10.09%
1-Year Return179.08%5.2%22.09%
3-Year Return789.97%13.08%35.68%
5-Year Return805.1%44.4%83.47%
10-Year Return294.22%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.35K2.35K40.00M458.00K458.00K[{"date":"2019-12-31","value":0.01,"profit":true},{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.15,"profit":true},{"date":"2023-12-31","value":1.15,"profit":true}]
Cost of Revenue512.11K627.85K-346.00K679.62K[{"date":"2019-12-31","value":75.35,"profit":true},{"date":"2020-12-31","value":92.38,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":50.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(509.76K)(627.85K)40.00M112.00K(679.62K)[{"date":"2019-12-31","value":-1.27,"profit":false},{"date":"2020-12-31","value":-1.57,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.28,"profit":true},{"date":"2023-12-31","value":-1.7,"profit":false}]
Gross Margin(21682.69%)(26705.49%)100.00%24.45%(148.39%)[{"date":"2019-12-31","value":-21682.69,"profit":false},{"date":"2020-12-31","value":-26705.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":24.45,"profit":true},{"date":"2023-12-31","value":-148.39,"profit":false}]
Operating Expenses53.41M66.01M97.68M66.23M67.15M[{"date":"2019-12-31","value":54.68,"profit":true},{"date":"2020-12-31","value":67.58,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.8,"profit":true},{"date":"2023-12-31","value":68.74,"profit":true}]
Operating Income(53.87M)(74.28M)(73.31M)(66.12M)(67.83M)[{"date":"2019-12-31","value":-5386662821,"profit":false},{"date":"2020-12-31","value":-7427700000,"profit":false},{"date":"2021-12-31","value":-7331300000,"profit":false},{"date":"2022-12-31","value":-6611600000,"profit":false},{"date":"2023-12-31","value":-6783090200,"profit":false}]
Total Non-Operating Income/Expense3.05M6.87M(1.70M)9.60M22.29M[{"date":"2019-12-31","value":13.67,"profit":true},{"date":"2020-12-31","value":30.83,"profit":true},{"date":"2021-12-31","value":-7.63,"profit":false},{"date":"2022-12-31","value":43.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(51.41M)(65.00M)(55.59M)(68.45M)(55.21M)[{"date":"2019-12-31","value":-5140556983,"profit":false},{"date":"2020-12-31","value":-6500000000,"profit":false},{"date":"2021-12-31","value":-5558700000,"profit":false},{"date":"2022-12-31","value":-6844800000,"profit":false},{"date":"2023-12-31","value":-5521218000,"profit":false}]
Income Taxes(9.53M)146.00K(18.00K)253.00K(632.44K)[{"date":"2019-12-31","value":-3765.07,"profit":false},{"date":"2020-12-31","value":57.71,"profit":true},{"date":"2021-12-31","value":-7.11,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-249.98,"profit":false}]
Income After Taxes(41.88M)(65.15M)(55.57M)(68.70M)(54.58M)[{"date":"2019-12-31","value":-4187994965,"profit":false},{"date":"2020-12-31","value":-6514600000,"profit":false},{"date":"2021-12-31","value":-5556900000,"profit":false},{"date":"2022-12-31","value":-6870100000,"profit":false},{"date":"2023-12-31","value":-5457973900,"profit":false}]
Income From Continuous Operations(31.94M)(65.15M)(55.57M)(68.70M)(50.69M)[{"date":"2019-12-31","value":-3194100000,"profit":false},{"date":"2020-12-31","value":-6514600000,"profit":false},{"date":"2021-12-31","value":-5556900000,"profit":false},{"date":"2022-12-31","value":-6870100000,"profit":false},{"date":"2023-12-31","value":-5068800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(41.88M)(65.15M)(55.57M)(68.70M)(54.37M)[{"date":"2019-12-31","value":-4187994965,"profit":false},{"date":"2020-12-31","value":-6514600000,"profit":false},{"date":"2021-12-31","value":-5556900000,"profit":false},{"date":"2022-12-31","value":-6870100000,"profit":false},{"date":"2023-12-31","value":-5436900000,"profit":false}]
EPS (Diluted)(3.09)(2.47)(0.97)(1.11)(0.47)[{"date":"2019-12-31","value":-309,"profit":false},{"date":"2020-12-31","value":-247,"profit":false},{"date":"2021-12-31","value":-97,"profit":false},{"date":"2022-12-31","value":-111,"profit":false},{"date":"2023-12-31","value":-47,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VRNA
Cash Ratio 12.02
Current Ratio 13.03
Quick Ratio 12.88

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VRNA
ROA (LTM) -28.05%
ROE (LTM) -78.03%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VRNA
Debt Ratio Lower is generally better. Negative is bad. 0.66
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VRNA
Trailing PE NM
Forward PE NM
P/S (TTM) 781.21
P/B 34.49
Price/FCF NM
EV/R 762.27
EV/Ebitda NM
PEG NM

FAQs

What is Verona Pharma PLC ADR share price today?

Verona Pharma PLC ADR (VRNA) share price today is $53.22

Can Indians buy Verona Pharma PLC ADR shares?

Yes, Indians can buy shares of Verona Pharma PLC ADR (VRNA) on Vested. To buy Verona Pharma PLC ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Verona Pharma PLC ADR be purchased?

Yes, you can purchase fractional shares of Verona Pharma PLC ADR (VRNA) via the Vested app. You can start investing in Verona Pharma PLC ADR (VRNA) with a minimum investment of $1.

How to invest in Verona Pharma PLC ADR shares from India?

You can invest in shares of Verona Pharma PLC ADR (VRNA) via Vested in three simple steps:

  • Click on Sign Up or Invest in VRNA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Verona Pharma PLC ADR shares
What is Verona Pharma PLC ADR 52-week high and low stock price?

The 52-week high price of Verona Pharma PLC ADR (VRNA) is $55.91. The 52-week low price of Verona Pharma PLC ADR (VRNA) is $11.39.

What is Verona Pharma PLC ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Verona Pharma PLC ADR (VRNA) is 34.49

What is the Market Cap of Verona Pharma PLC ADR?

The market capitalization of Verona Pharma PLC ADR (VRNA) is $4.49B

What is Verona Pharma PLC ADR’s stock symbol?

The stock symbol (or ticker) of Verona Pharma PLC ADR is VRNA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top